Drugs / K562-GM
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01313429 | Mar 2011 → Feb 2020 | epithelial neoplasm, melanoma, pleural cancer, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01143545 | Dec 2010 → Feb 2015 | esophageal cancer, lung cancer, malignant pleural mesothelioma, sarcoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K562-GM | “patients with sarcomas, melanomas, germ cell tumors, or epithelial malignancies metastatic to lungs, pleura or mediastinum will be vaccinated with irradiated K562...” NCT01313429 ↗1“K562-GM allogeneic tumor cell vaccines” NCT01143545 ↗ |
| Modality | Vaccine | “allogeneic tumor cell vaccines” NCT01143545 ↗ |
| Route | Subcutaneous | “vaccinated via subcutaneous intradermal injection” NCT01143545 ↗ |